scholarly journals A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

2011 ◽  
Vol 63 (12) ◽  
pp. 3918-3930 ◽  
Author(s):  
Richard Furie ◽  
Michelle Petri ◽  
Omid Zamani ◽  
Ricard Cervera ◽  
Daniel J. Wallace ◽  
...  
Lupus ◽  
2020 ◽  
Vol 29 (4) ◽  
pp. 426-430 ◽  
Author(s):  
O Shamriz ◽  
S H Yahia ◽  
Y Ramot ◽  
N Agmon-Levin ◽  
Y Tal

Belimumab, an anti-B-lymphocyte stimulator monoclonal antibody, was recently approved for the treatment of systemic lupus erythematosus. Alopecia areata is characterized by an acute immune-mediated hair loss. Herein, we report on three adult systemic lupus erythematosus patients who developed alopecia areata in association with belimumab treatment. Alopecia areata was resolved in all three patients and belimumab was discontinued in two of them. Thus, in the current report, we explore the plausible link between alopecia areata and belimumab.


2009 ◽  
Vol 60 (11) ◽  
pp. 3400-3409 ◽  
Author(s):  
Sandy D. Hong ◽  
Andreas Reiff ◽  
Hai-Tao Yang ◽  
Thi-Sau Migone ◽  
Christopher D. Ward ◽  
...  

2003 ◽  
Vol 48 (12) ◽  
pp. 3475-3486 ◽  
Author(s):  
William Stohl ◽  
Samy Metyas ◽  
Soon-Min Tan ◽  
Gurtej S. Cheema ◽  
Bonifacia Oamar ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document